Equal Partnership with AFT Pharmaceuticals for Development of a Novel Locally- Acting Product Candidate in Burning Mouth Syndrome (HY-090) Strengthening Strategic Partnership with AFT Pharmaceuticals Following the Success of the Maxigesic® IV Collaboration Liège, Belgium – 21 December 2023, 06:30PM CET – Regulated information –…
PFI21 December 2023













